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Background: During the last two decades, protein aggregation at all organismal levels,
from viruses to humans, has emerged from a neglected area of protein science
to become a central issue in biology and biomedicine. This article constitutes a
risk-based review aimed at supporting an etiologic scenario of selected, sporadic,
protein-associated, i.e., conformational, neurodegenerative disorders (NDDs), and their
vascular- and metabolic-associated ailments.
Methods: A rationale is adopted, to incorporate selected clinical data and results from
animal-model research, complementing epidemiologic evidences reported in two prior
articles.
Findings: Theory is formulated assuming an underlying conformational transmission
mechanism, mediated either by horizontal transfer of mammalian genes coding for
specific aggregation-prone proteins, or by xeno-templating between bacterial and host
proteins. We build a few population-based and experimentally-testable hypotheses
focusing on: (1) non-disposable surgical instruments for sporadic Creutzfeldt-Jakob
disease (sCJD) and other rapid progressive neurodegenerative dementia (sRPNDd),
multiple system atrophy (MSA), and motor neuron disease (MND); and (2) specific
bacterial infections such as B. pertussis and E. coli for all forms, but particularly for late-
life sporadic conformational, NDDs, type 2 diabetes mellitus (T2DM), and atherosclerosis
where natural protein fibrils present in such organisms as a result of adaptation to the
human host induce prion-like mechanisms.
Conclusion: Implications for cohort alignment and experimental animal research are
discussed and research lines proposed.
Keywords: epidemiological patterns, etiology of conformational protein deposits, templating underlying
risk/progression, disease induction vs. transmission in amyloid, multidisciplinary research overlaps
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INTRODUCTION
During the last two decades, protein aggregation at all
organismal levels, from viruses to humans, has emerged from
a neglected area of protein science to become a central
issue in biology and biomedicine (Villar-Piqué and Ventura,
2012) The expanding knowledge in the field has particularly
benefited our understanding of neurodegenerative disorders
(NDDs). At the present time, it is widely acknowledged
that templating (the basic mechanism generating protein
misfolding, aggregation, deposit, and cell-to-cell transfer of
certain pathogenic proteins) would be able to explain many
features of the subclinical course and clinical manifestations of
NDDs (Warren et al., 2013). Transcellular disease propagation
of the pathogenic protein along existing anatomic structures
(neural networks) would also explain the progression from
the varied clinical patterns of NDDs (denoted as phenotypic
heterogeneity) to a phenotypically converging, similar status,
where a wide loss of cognitive, motor and sensory functions occur
(Warren et al., 2013).
In a prior article, we selected 11 neurodegenerative
conditions defined by clinical, neuropathological and
biochemical features expressing different sets of single or
combined misfolded protein deposits, and described life-
course-related epidemiologic features (age-specific incidences
and disease risk factors or disease progression predictors),
thereby allowing for a meaningful, framed and unifying view
of each disorder and its post-mortem biochemical signature
(de Pedro-Cuesta et al., 2015). At a second step, we used
a modified definition of the driver concept proposed by
Sutherland to identify risk factors of specific proteins affecting
different NDDs (Sutherland et al., 2011) and, having in mind
the common amyloid nature of the pathogenic proteins
involved, we identified selected traits of the epidemiology
of sporadic, protein-associated, i.e., conformational, NDDs
(sCNDD) useful for interpreting epidemiologic findings and
relationships of the entities listed in Table 1 (Gunnarsson
et al., 1996; Marmorstein et al., 2002; Peng et al., 2005; Irwin
et al., 2013; Prusiner et al., 2015; de Pedro-Cuesta et al.,
2016). In this third article we face a cumulative etiologic
approach taking into account recent experimental data on
transmissibility of multiple system atrophy (MSA; Prusiner et al.,
2015).
Accordingly, the purpose of this work was: (a) to complement
and anchor the interpretation of each driver with selected
results of clinical or animal-model research; (b) to propose
etiologic theory pointing to basic mechanisms and specific
causal hypotheses testable by study designs, for epidemiologic or
experimental research; and (c) in line with recent initiatives, to
propose public health developments.
SEARCH STRATEGY AND SELECTION
CRITERIA
References for this review were identified by searches used in
prior articles (de Pedro-Cuesta et al., 2015, 2016), by diverse
searches of MEDLINE with limits from 1995 to September
2015, relevant for entities on study, and reference lists from
relevant articles. Reports in MEDLINE in all languages, using
each of the following diagnostic search terms combined with
etiology, i.e., dementia, Creutzfeldt-Jakob syndrome, motor
neurone disease (MND), amyotrophic lateral sclerosis (ALS),
fronto-temporal dementia (FTD), MSA, Parkinson’s disease
(PD), Lewy body disease (LBD), Alzheimer’s disease (AD),
rapid progressive dementia, age-related macular degeneration
(AMD) and Huntington’s disease (HD). There were no language
restrictions. Driver specific reference lists were built. The final
reference list consisted of a compendium of an approximately
twice the size of full-text consultation work. As a literature
review based proposal, the study does not require ethical
assessment.
DATA SUPPORTING AMYLOID-RELATED
ETIOLOGY ACCORDING TO SPECIFIC
DRIVERS AND SUCCINCT THEORY
Driver 1. Low Age-at-Exposure Related
Susceptibility to Environmental Exposure
Effects
Driver 1 builds on the following specific epidemiologic
observations: (a) age at first major whooping cough epidemic and
PD incidence in Iceland; (b) bovine spongiform encephalopathy
and variant Creutzfeldt-Jakob disease (vCJD); (c) age at first
human growth hormone (hGH) treatment and accidentally
transmitted CJD (atCJD) in the UK; and (d) risk of sporadic
Creutzfeldt-Jakob disease (sCJD) from routine surgery followed
by a ≥20-year latency period in Denmark and Sweden.
When fitted to a linear model, risk of PD increased with age
at first whooping cough epidemic, a proxy of median age at
BP infection (de Pedro-Cuesta et al., 1996). The susceptibility
function for vCJD followed an inverted V shaped profile
peaking at approximately 10 years. For sCJD, we observed
that surgery at juvenile age (<30 years) yielded the highest
risk (OR 12.80; 95% CI 2.56–64.0). Associations between
developmental factors and risk of AD (Savica et al., 2013)
and PD (Barlow et al., 2007) might support driver 1 validity
for late-life sCNDD (for a review see de Pedro-Cuesta et al.,
2016).
Complementary Findings
• Neuropathologically proven AD associated with atCJD has
been reported in a young patient who received a dura mater
graft (Preusser et al., 2006).
• A significantly high incidence of MND (based on three
cases) has recently been described in a young cohort of hGH
recipients in the USA (Irwin et al., 2013).
• Potential host-to-cell induction of α-synuclein degeneration
from patients diagnosed with PD who received
fetal/embryonic tissue grafts, and disease induction by
seeding in the α-synuclein and tau mouse models, supported
the inference of induction of late-life sCNDD in fetal cells
(Luk et al., 2012b; Morales et al., 2012; Olanow and Brundin,
2013).
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TABLE 1 | Modified from de Pedro-Cuesta et al. (2016) Main biochemical, epidemiologic and other features of sCNDDs and other sporadic human
amyloid disorders involved in the proposed etiologic framework.
Entity or neuropathologically Main protein Reported outbreaks Annual incidence per million M/F ratio
related entities deposit person-years or
prevalence at death†
Sporadic Genetic
Creutzfeldt-Jakob disease APrP vCJD UK, Ireland, France, Spain 1 0.1 1.1/1
Amyotrophic lateral sclerosis (ALS) and Ubiquitin, MAPT (tau), ALS Skaraborg county (Sweden; 10 1 1.5–2/1
frontotemporal dementia (FTD) SOD, TDP-43/FUS Gunnarsson et al., 1996).
US human growth hormone
treated cohort (Irwin et al., 2013)
Parkinson’s disease (PD), α synuclein – – 100 10 1.5–2.5/1
Lewy body disease (LBD) for PD
and multiple system atrophy (MSA)
Alzheimer’s disease β amyloid, Tau – – 1000 100 0.92/1
Late age-related macular EFEMP1 wild-type – 1000 Unknown 0.95/1
degeneration (AMD) (Marmorstein et al., 2002)
T2 diabetes mellitus (T2DM) Langerhans Islet peptide – – – – –
Sporadic cerebral β amyloid wild-type – – – – –
amyloid angiopathy
Senile systemic amyloidosis (SSA), Transthyretin wild-type – – – 25% ≥85 years† -
heart failure and myocardial infarction,
aortic aneurism, narrow spinal channel
Medin arteriopathy (Peng et al., 2005) Lactadherin – – – – –
Transmission among individuals proven for CJD and PD, not for MSA*.*From PD patient to fetal grafted cells. Brain extracts of MSA cases transmitted α synuclein
proteinopathy to TgM83+/− mice (Prusiner et al., 2015). † For SSA.
• Age-at-exposure related effect is a common characteristic
of neurodegeneration induced by neurotropic agents
(Fishman et al., 1985). In a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) parkinsonism model, selective
nigral neuronal toxicity in laboratory animals was
highest for the older rats and macaques (Langston
et al., 1987). This was attributed to age-related neuronal
pigmented deposit (relevant for accumulation of metabolic
residue and advanced glycation end-products), which
increases with age.
• Intracerebral injection of brain extracts containing aggregated
α-synuclein into young, α-synuclein-transgenic mice
stimulates the formation of α-synuclein lesions in the
host (Luk et al., 2012a; Mougenot et al., 2012).
• Experiments on different neurodegenerative disease models
supporting prion-like mechanisms (Jucker andWalker, 2013):
in seeding experiments with APP mice, the age of the host
at the time of inoculation can be a strong determinant of the
result (Jucker andWalker, 2013). A similar feature is displayed
by the male-mouse castration model of PD, which is only
efficient when castration is performed on 4- to 6-week-old
mice (Khasnavis et al., 2013).
• MSA, an α-synucleinopathy, has recently been transmitted in
cell and mouse models (Prusiner et al., 2015).
Theory
Early- and midlife proteinopathies and late-life sCNDD could
be induced or modulated by early-age exposures, regardless
of anatomic organs for contact and following a log-linear
age-related function. Mimicking age-at-exposure related effects
in animal models might be essential for supporting the biological
plausibility of epidemiologic observations.
Driver 2. Tridimensional Pattern: Direct
Relationships between Age at Peak
Incidence (or Age at Clinical Onset),
Incidence Magnitude, and Course (Clinical
Disease Duration)
The driver, described on the basis of sCJD, FTD, PD, LBD, AD,
and AMD data suggest that:
(a) the duration of the subclinical and clinical courses are related;
(b) low-incidence sCNDD progress rapidly, and those with
highest incidence progress slowly; and,
(c) agents (including modifiers) generating aggressive forms
might be less frequent or require more susceptibility than
those lying behind less severe forms which may display high
attack rates, i.e., they will affect large proportions of the
population.
Complementary Findings
• Age at peak age-specific incidence appears to be related to
protein propagation, as supported by observations of familial
AD, where mean ages at onset are determined by the Ab40/42
ratio (Duering et al., 2005).
• Prion models suggests that a lower prion protein inoculum
correlates with a longer incubation period (Gravenor et al.,
2003). Slow subclinical and clinical progression might
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correspond to long incubation period from low inoculum
exposures in experiments with animal models of prion diseases
(Gravenor et al., 2003).
• Acute toxic effects followed by residual effects might better
fit MPTP model patterns (Langston et al., 1987) than
those suggesting a persistently active etiologic mechanism or
multiple hits across the life course.
• After request to authors of recent surveys (Bjornsdottir et al.,
2013; Caslake et al., 2014) and positive answer for Icelandic
data, normalized reported age-specific incidence and median
age-at-onset of MSA in Iceland where plotted at a reported
figure for other CNDDs (de Pedro-Cuesta et al., 2015).
The MSA incidence curve fitted curves and peak values
intermediate between those for sCJD and PD (Figure 1;
Granieri et al., 1991; Gao et al., 1998; Baldereschi et al., 2000;
Will et al., 2000; Benito-León et al., 2004; de Lau et al., 2004;
Pocchiari et al., 2004; Fang et al., 2009; Chen and Lai, 2010;
Steenland et al., 2010; Owen et al., 2012; Bjornsdottir et al.,
2013; de Pedro-Cuesta et al., 2015).
Theory
This driver might point to two distinct etiologic sCNDD forms
differentiated by rapid progression, such as sCJD, ALS, and
some sporadic rapidly-progressing neurodegenerative dementias
(sRPNDds) with peak onset at age 70–75 years, and disease
duration <3 years and late-life sCNDD with later age at onset
and slower progression. When links with vascular lesions or
vascular risk factors (VRF) are considered, sCJD, LBD, AD,
and AMD would present and perhaps share vascular protein
deposits: this would not, however, apply to FTD, PD and MSA,
which are epidemiologically less closely related to VRF. Type
2 diabetes mellitus (T2DM) and vascular disease would be
particularly seen in sCNDD (including sRPNDds) with incidence
peaking after age 85 years. Prion strains and diverse entry routes
would determine the large variation of age at onset in hGH-
related atCJD, vCJD, and sCJD. High incidence of late-onset
sCNDD might correspond to high attack rates from ubiquitous
or widespread, tiny or low inoculum exposures and the opposite
or a combination (low incidence, high inoculum exposures) for
midlife-onset sCNDD, i.e., earlier-onset sCJD, ALS and earliest-
onset sRPNDdmay share prion-like entry or spreadmechanisms.
Driver 3. Shared, Age-at-Onset Related,
Genetic Risk Factors
We postulate that driver 3 reflects the effect of different
genes, which, either separately or by interaction, determine the
excess risk of several sCNDD, such as AD, CJD, and LBD
FIGURE 1 | Normalized age-specific incidence, incidence per million and survival for selected neurodegenerative disorders (NDDs). Modified from
de Pedro-Cuesta et al. (2015). Normalized age-specific incidence, age-adjusted incidence, and median clinical disease duration of different sporadic
protein-associated neurodegenerative disorders (sCNDDs), obtained either from reported data [amyotrophic lateral sclerosis (ALS), personally modified by Fang F,
sporadic Creutzfeldt-Jakob disease (sCJD)] or from registries [sporadic rapid progressive neurodegenerative dementia (sRPNDd) notified as suspected sCJD in
Spain for 1995–2011, obtained from the Spanish CJD surveillance registry] and obtained from authors for multiple system atrophy (MSA). References for Figure 1
(Granieri et al., 1991; Gao et al., 1998; Baldereschi et al., 2000; Will et al., 2000; Benito-León et al., 2004; Pocchiari et al., 2004; de Lau et al., 2004; Fang et al.,
2009; Chen and Lai, 2010; Steenland et al., 2010; Owen et al., 2012; Bjornsdottir et al., 2013). (a) 85–89 years is equivalent to 85 years and older for sCJD, ALS,
Lewy body disease (LBD), Parkinson’s disease (PD), and sRPNDd; (b) 90–94 years is equivalent to 90 years and older for age-related macular degeneration (AMD)
and frontotemporal dementia (FTD).
Frontiers in Aging Neuroscience | www.frontiersin.org 4 June 2016 | Volume 8 | Article 138
de Pedro-Cuesta et al. Etiologic Framework for Conformational Disorders
(Wilson et al., 1994; Zende et al., 2013). For instance, positive
findings in sCJD and AD for APOEε4, CALHM1 and BACE1
polymorphisms underscore the interplay between APP, Aβ
oligomers, ApoE, PrP, and BACE1 in sCJD and AD, and suggest
that agingmay partly modulate disease pathologies through these
key players (Calero et al., 2012a,b).
Complementary Findings
• It is accepted today that the animal models which best
reproduce atherothrombotic disease and AD are those based
on ApoE-knockout mice (Zaragoza et al., 2011).
• Diverse reviews on APOE gene effects show that the ApoE4
allele is linked to moderate excess risk for arterial hypertension
and ischemic heart disease (Haan and Mayeda, 2010),
intracerebral and lobar bleeding (Biffi et al., 2010), coronary
heart disease, stroke, peripheral artery disease, and diabetes
mellitus (Eichner et al., 2002).
• The common presence of APOE, BACE1 (and other genes,
as suggested by total genome studies) linked to βA and other
proteins calls for a role for these or other genes in a selected
group of sCNDD, as well as in atherosclerosis.
• sCJD was initially misdiagnosed 4% of times as a vascular,
non-autoimmune disease, including stroke (Paterson et al.,
2012), perhaps indicating the presence of a vasculopathy
in sCJD.
Theory
APOE4 interacts with etiologic environmental factors for several
disorders, i.e., sporadic AD, LBD, AMD, vascular dementia,
atherosclerosis, or other forms of vascular disease such as heart
failure, myocardial infarction, senile systemic angiopathy, and
aortic aneurism. We also hypothesize that shared susceptibility
genes for selected sCNDD and atherosclerosis mediate the
effects of single pluripotential exposures, i.e., due to the same
inoculum, or generated by the same mechanism. High-risk
birth cohorts might share excess risk for several conformational
disorders.
Driver 4. Personal Risk Factors
This driver is related to a set of multiple variables, such as
clinical signs and symptoms (diagnoses), behavioral patterns
(health-related habits), and educational factors, which constitute
the group of well-established associations with specific sCNDD.
When discussing driver 1, reference was made to some
personal factors potentially due to an age-at-exposure related
effect, fitting under the umbrella of developmentally-related
effects, i.e., education in AD, cranial perimeter in north-
Korean women, or early symptoms, such as scoliosis or
constipation in PD (Stern et al., 2012). This multifaceted
and disperse panorama might be too wide for a satisfactory
etiologically oriented approach to sCNDD. Insofar as the focus
is AD or dementia, however, the driver notion constitutes
the best structured etiologic and public health approach.
A recent review addressing arterial hypertension, T2DM,
hypercholesterolemia, physical activity, depression educational
attainment, and smoking history (all personal factors) and
risk of AD emphasized the non-independent nature of such
factors (Norton et al., 2014). Correcting for dependence, the
authors estimated that, assuming causality underlying the
associations, the AD attributable proportion reduced by a
control of 10% of risk factors per decade would be 8.3%
worldwide in 2050 (Norton et al., 2014). When these risk
factors were considered with regard to other sCNDD, the
established association patterns were weaker. For instance,
no excess risk for PD from T2DM was observed, when PD
onset was controlled for Simon et al. (2007) and Palacios
et al. (2011). In contrast, other studies reported modest
increases (Schernhammer et al., 2011; Sun et al., 2012).
We believe that the outline shown in Figure 2 (Norton
et al., 2014) illustrates the state of art in public health
prevention of sCNDD (entity-specific and mainly based on
type-4 drivers). We propose that a complementary etiologic
overview of sCNDD from personal factors should incorporate
goals and interpretations from other drivers, and driver 1 in
particular, for late-life sCNDD, as illustrated by a potential
multiple outcome that combines (though not necessarily in the
same individual) protein deposits generating sCNDD, T2DM
as a result of Islet amyloid peptide (IAPP), and vascular
wall lesions from amyloid deposits such as Aβ, lactadherin
(Peng et al., 2005) and transthyretin (TTR; Coelho et al.,
2013).
Complementary Findings
• There is increasing biologic evidence supporting the
contention that fibrillar amyloid beta protein present in
atheroma promotes atherogenesis (Medeiros et al., 2004).
• Bacterial vectors may transport inclusion bodies having
amyloid-like properties able to seed their soluble counterparts
FIGURE 2 | Outline of a proposed Public Health Prevention Model I for
a single neurodegenerative disorder (Norton et al., 2014), e.g.,
Alzheimer’s disease (AD). Overlaps indicate risk-factor associations. Arrows
indicate assumed direct causality.
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and induce cytotoxicity in eukaryotic cells (for a review see
Wang, 2009).
• A growing body of evidence suggests that platelet activation
can mediate angiopathy in AD (Zhang et al., 2013). Medin-
deposits, i.e., lactadherin, underlie age-associated arterial
lesions (Peng et al., 2005).
• Colocalization studies of IAPP and Aβ in islet amyloid in
type 2 diabetic patients, and Aβ deposits in brains of patients
with AD show heterologous seeding between IAPP and Aβ,
a phenomenon that may represent a molecular link between
T2DM and AD (Oskarsson et al., 2015).
Theory
The view based on personal factors and the amyloid perspective
on sCNDD suggests that a considerable part of the associations
with late-life sCNDD, atherosclerosis, and T2DM might conceal
confounding or reverse association (early manifestations of
subclinical disease). This view, if confirmed, might complement
the rationale for prevention of sCNDD, T2DM, and part
of atherosclerosis, where measures for control of shared
etiologic mechanisms underlying sCNDD, T2DM, and various
angiopathies are proposed. Driver 4 contribution to theory is
summarized as a potential switch of the roles attributed to a
direct relationship between risk factors and sCNDD in Figure 2,
to those outlined in Figure 3. Most of these associations are in
part interpreted as confounding or reverse causality, and direct
causality is assigned to a higher level shared by defined amyloid
disorders.
Driver 5. Environmental Risk Factors
As a relevant part of our hypothesis we selected invasive medical
procedures (mainly surgery) as a risk factor for sCJD and BP
infection as a risk factor for PD.
FIGURE 3 | Outline of an expanded Public Health Prevention Model I to
Model II, assuming an age-at-onset related continuum for various
late-age NDDs, and that the unfolded protein response explains—at
least in part—the reported associations for diverse conformational
neurodegenerative, vascular degenerative and metabolic disorders
(type 2 diabetes mellitus, T2DM). Modified from de Pedro-Cuesta et al.
(2016).
Invasive Medical Procedures and Risk of Midlife
sCNDD
The hypothesis of a surgical (and blood-transfusion-related) risk
of sCJD is based on a few reports on CJD among patients
exposed to neurosurgical instruments used on a patient with
subclinical or clinically manifested CJD, and on observations
from a register-based population case-control study on routine
hospital surgery followed by a lag of over 20 years, with
retina surgery being associated with sCJD, on the basis of
three cases with a mean latency of 11 years (de Pedro-
Cuesta et al., 2011). Aside from one Italian study (Puopolo
et al., 2011), however, confounding by surgically-linked blood
transfusion was not controlled for, and no positive association
between neurosurgical procedures and CJD has been shown.
Inconsistent findings for risk from blood transfusion have been
reported.
Complementary Findings
• In 1994, infectivity from tissues such as liver and lung
was shown in CJD mouse models (Brown et al., 1994).
Subsequently, transmission of prion disease from tissue
remnants adhered to surgical instruments was confirmed
(Weissmann et al., 2002).
• Injection of mouse brain extract containing Aβ seeds (similar
to those found in the AD brain) into the peritoneal cavity
of mice genetically engineered to develop amyloid plaques
(murine model of AD) accelerates Aβ deposition in the host
brain (Eisele et al., 2010).
• βA deposition can be induced by injection of AD brain extracts
into animals, which, without exposure to this material, would
never otherwise develop these alterations (Morales et al.,
2012).
• An independent line of evidence builds on seeding
experiments from curli for E. coli and other organisms
in Amyloidosis A (Lundmark et al., 2005).
• The long incubation suggested for sCJD from routine surgery
undergone at high-susceptibility ages would suggest that such
mechanisms may only be relevant for rapid-course sCNDD,
so that the latency period for late-life NDDs might exceed the
human life course.
• The increased resistance to protein degradation in amyloid
may provide some consistency with prion theory.
• Recently some patients treated with cadaveric hGH who
subsequently developed iatrogenic CJD also showed evidence
of βA deposition in their pituitary glands (Jaunmuktane et al.,
2015; Frontzek et al., 2016).
• Brain extracts ofMSA cases, in general aged at onset≤75 years,
transmitted an α-synuclein proteinopathy to TgM83+/−mice
being the prionic nature of some α-synuclein recognized
(Prusiner et al., 2015).
Theory
On the basis of register-based epidemiologic studies on surgical
risk of sCJD suggesting age-related susceptibility, the suggested
associations of ALS and incidence peaking at a similar age,
we propose that sCJD, ALS and some sRPNDds and MSA
with onset below age 75–79 years are transmitted by routine
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surgery and transfusion of blood or blood derivatives at
juvenile age.
Host-Adapted Human Pathogens. BP and Late-Life
sCNDD
The association between age at first major whooping cough
outbreak (MWCO) and PD constitutes an important observation
in Iceland, reinforced by negative results for birth-cohort effects
in continental populations. Considered as a quasi-experiment, it
is consistent with the high prevalence and incidence of PD among
the Faroe Islanders and Greenland Inuit (Wermuth et al., 2002,
2008). The excess risk of PD as a long-term biological effect of
BP infection was attributed to Pertussis toxin (de Pedro-Cuesta
et al., 1996). Since PD shares protein deposits (for a review see
Sutherland et al., 2011 ) with MSA, LBD, and AD, BP infection
in genetically susceptible young individuals might be proposed as
an environmental driver for late-life sCNDD such as MSA, PD,
LBD, AD, and AMD.
Complementary findings
• BP has historically been harbored by human populations
and its dynamic still remains uncontrolled by vaccines.
Despite the fact that undesired protein aggregation can have
negative consequences for the cell, functional aggregation-
prone regions and aggregates are essential for life. For example,
in some enterobacteria, amyloid aggregates appear to mediate
bacterial adhesion, biofilm development, and host invasion
(de Groot et al., 2012). Human coexistence with commensal
or pathogenic bacteria such as BP might have led to the
interaction of bacterial aggregated proteins with aggregation-
prone sequences from the host, resulting in xeno-templating.
• A mutation in the PS2 gene (M239V) neutralizes the
toxicity mediated by the Pertussis toxin, suggesting that this
toxin shares pathological mechanisms with some AD-mutant
variants (Abe et al., 2004).
• Biological agents acting in the distant past may have changed
as a result of human interventions, such as vaccination
(Cummings et al., 2004).
• Horizontal gene transfer research on the Tohama I strain of
BP dating back to 1950 may provide source information for
understanding the pathobiology of BP and the potential effect
in Japanese cohorts currently aged 70 years (Preston, 2005),
particularly if curli can be identified in such strain.
• The rationale suggested for E. coli (see ‘‘Driver 7. Invariant
ratio of sCNDD Incidence/Genetic CNDD Incidence, Across
Entities’’ Section) would also be valid for BP. Seeding of
naturally occurring protein fibrils from BP, as experimentally
observed with curli from E. coli (Lundmark et al., 2005), might
be hypothesized as biological pluripotential mechanisms
underlying BP infection as a causal factor of PD, AD, and
diverse late-life sCNDD.
• Mechanisms for adaptation to humans seem to have occurred
in the BP precursor, B. pseudopertussis, at an earlier time,
taking place for BP by gene loss (Diavatopoulos et al.,
2005). B. pertussis infection damages nasal ciliated epithelium,
a structure which transfers uranium to brain along olfactory
nerve bundles (Wilson et al., 1991; Ibáñez et al., 2014).
• The clear, saw-teeth, birth-cohort pattern seen for PD
incidence and attributed to the periodic pattern of BP
epidemics in Iceland suggests that a similar effect of agents,
other than airborne BP epidemic agents, such as influenza or
measles, is unlikely. However, a supplementary action through
the gastrointestinal tract is not ruled out. The shared early loss
of olfactory function and lesions described in sCJD, FTD, PD,
and ADmight point to a potential effect of BP infection on the
clinical profile of sCNDD (Magerova et al., 2014).
• In addition to airborne agents, synthetic amyloid-like
biomaterials and oral agents such as those described for vCJD
or food have been proposed, given the high content in protein
fibrils (Westermark and Westermark, 2010).
• In accordance with the induction of AApoAII amyloidosis by
various amyloid fibrils, though best by mouse AApoAII(C)
amyloid (Fu et al., 2004), the expected key active element
mediated by the human microbiome might be a natural fibril
genetically related to human pathology.
Theory
Human-adapted agents integrating human genome such as BP
able to generate natural protein fibrils might generate different
late-life sCNDD by pluripotential mechanisms in accordance
with the individual susceptibility. BP may act through nasal and
gastrointestinal epithelia. Systemic action across the endoplasmic
reticulum (ER) and vascular endothelium might be plausible.
Driver 6. Endoplasmic Reticulum Stressors
or General Drivers
Protein folding is a basic mechanism regulating cell function
and survival (Bernales et al., 2012). Variables related to the
unfolding protein response (UPR) in ER and mitochondria,
acting either as stressors or as a result of altered pathways
might be epidemiologically captured, reflecting some of the
most characteristic drivers of the expanded NDD paradigm.
They may affect sCNDD, T2DM, and atherosclerosis potentially
related with senile systemic angiopathy and cerebral amyloid-
β (Aβ) angiopathy (CAA; linked to myocardial infarction and
dementia or AD, respectively), with different underlying amyloid
deposits, i.e., wild-type TTR, lactadherin, and beta amyloid. In
accordance with the original general proposal, such drivers may
affect membrane or secretory tissues such as those resulting
in estrogen and testosterone deficits, and midlife VRF such as
metabolic syndrome and T2DM. Relationships may be complex
if some of the ER stress effects or causes constitute T2DM or
sCNDD comorbidity, i.e., obesity.
Complementary Findings
• The role of endocrine factors in sCNDDs risk is supported
by clinical and animal research. Since premenopausal
oophorectomy is an iatrogenic factor, at least some
associations of estrogen deficit may be considered to act
outside the most susceptible lifetime points (driver 1), such as
juvenile age.
• In addition to the estrogen deficit in dementia, AD pathology,
T2DM, and atherosclerosis discussed elsewhere (de Pedro-
Cuesta et al., 2016), an impact on synuclein-related sCNDD
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may be suggested, since some animal studies implicate a
role for estrogen in protecting the nigrostriatal dopaminergic
functions (Becker, 1990; Morissette and Di Paolo, 1993).
• However, estrogen therapy with esterified estrogen use in
combination with progestin was recently linked to a 6-fold
excess risk of PD (Lundin et al., 2014). While castration,
conducted no later than at 4–5 weeks, makes the male-
mouse model support the etiologic role of testosterone
deficit in PD (Khasnavis et al., 2013), it may also convey
insights into the driver-1 effect better than does andropause
mimicry.
• The fact that some endocrine deficits, i.e., testosterone, are
linked to risk of other endocrine disorders raises questions
about a shared, unidentified etiologic cause affecting secretory
systems.
• Complex links are suggested for T2DM: T2DM could be also
taken as a general driver, since it is associated with risk of
both FTD (Golimstok et al., 2014) and AD (Jayaraman and
Pike, 2014), and at the same time constitutes an outcome of
testosterone depletion (Kapoor et al., 2006; Lage et al., 2007).
• The relationship of ER stress and vascular wall pathology
may be persistent, since increased ER stress was identified in
atherosclerotic plaques linked to coronary syndrome (Myoishi
et al., 2007).
• The UPR in ER may be affected by environmental insults
and genetic modifiers which hamper biosynthesis of steroids,
cholesterol and many lipids (Kaufman, 2002).
• We believe that the amyloid perspective may serve as a
reference for etiologic thinking, where shared determinants
of early amyloid deposits in myocardial or cerebral vessels,
i.e., the tau/AD pathology (Chui et al., 2012) are plausible.
Chronic endocrine disorders such as estrogen or testosterone
deficits might not yet have been identified as conformational
disorders.
Theory
Figure 3 depicts a hypothetical etiologic scenario modified
from Figure 2, where different amyloid deposits shared by
sCNDD, vascular disorders and a number of endocrine entities or
functions, determine late-life human pathology as a result of ER
stressors or poor UPR. As a complement, some endocrine factors
of a different origin (i.e., oophorectomy or specific estrogen
therapies) might also constitute risk factors for conformational
disorders.
Driver 7. Invariant Ratio of sCNDD
Incidence/Genetic CNDD Incidence,
Across Entities
This driver applies basically to genetic CNDDs determined by
point mutations. The ratio, best known when defined by a proxy
value, namely, the proportion of incident disease corresponding
to familial forms, tends to increase due to the progressive
improvement in the identification of such mutations, and may
reach 25% in selected sCNDD. This feature, emphasized by
Soto and Estrada (2008), has long been recognized, despite
the fact that this proportion is higher in a few populations
(Israeli Jews, or populations with genetic clusters, e.g., Slovenia
for CJD). Similarly low proportions have been described for
genetic vs. sporadic forms of T2DM. The proportion is less
clearly perceived for AMD where mutated or wild-type EFEMP1
has been described, and atherosclerosis forms, such as SSA,
heart failure and aortic aneurysm (Westermark andWestermark,
2010), where wild-type TTR deposits have been described but
an incidence or case series reference for the sporadic form is
lacking.
Complementary Findings
• The ecologic relationship between sporadic genetic forms
may suggest a causal link between genetic CNDDs resulting
from point mutations and the corresponding sCNDD forms.
Since the predominant protein signature of a specific
sCNDD frequently corresponds to that of its genetic CNDD
form, one might speculate that, ontogenically speaking,
sCNDD forms might be considered secondary to genetic
ones in terms of numbers and biochemical similarity
(Parcerisas et al., 2014).
• In a prior article (de Pedro-Cuesta et al., 2016), we proposed
that the most relevant field of knowledge for driver 7 and
assessment of the role of vectors in sCNDD might be gene
transfer from human to bacterial human pathogens. A first
key issue would be the potential of human sequences to
make the hosted agent generate misfolded proteins, resulting
in infective natural fibrils with a biochemical signature
determined by the transferred genetic material. The hypothesis
would require an impact on sporadic atherosclerosis of
mutations other than those seen in the TTR gene and Notch
1 present in Cerebral Autosomal-Dominant Arteriopathy
with Subcortical Infarcts and Leukoencephalopathy
(CADASIL), but the high nonspecific potential of natural
and synthetic protein fibrils to enhance the amyloid
response during inflammation might explain cross-effects
(Fu et al., 2004).
• In this essay, we provide an example of such a potential process
which might have been identified, namely, that of E. coli.
It has been estimated that more than 17% of the genetic
material of E. coli (an enterobacterium hosted by humans;
Lawrence and Ochman, 1997), whose curli, natural protein
fibrils, have been used in animal models of A-amyloidosis by
natural fibril-seeding, is the result of horizontally transferred,
protein-coding DNA over several million years (Lawrence and
Ochman, 1997; Lundmark et al., 2005).
• Since inflammation is required for templating, the role of
E. coli might be mediated by gastrointestinal infections
at a young age. In 2003, Braak and associates proposed
that transneuronal transmission of pathologically altered
α-synuclein from the enteric nervous system to the brainstem
might occur in PD (Braak et al., 2003). Various heterogeneous,
natural and synthetic amyloid fibrils induced AApoAII
amyloidosis (Fu et al., 2004). This process could be compatible
with a proportion of cases being determined by other
mechanisms or entry sites such as the oral cavity (Olsen and
Singhrao, 2015). In contrast, SB Prusiner suggests that the
late onset of heritable NDDs, like their sporadic counterparts,
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may reflect a stochastic nature of prion formation
(Prusiner, 2013).
• Based on epidemiologic and laboratory research, it has been
proposed that several infectious agents are linked to different
NDDs: Nocardia sp. and BP to parkinsonism (Kohbata and
Beaman, 1991; de Pedro-Cuesta et al., 1996), and recent
adeno-associated viral vectors provide excellent α-synuclein
models of PD (Lindgren et al., 2012). Similarly, Herpes simplex
virus type 1 (HSV-1), in conjunction with apolipoprotein E4
(ApoE4) from a murine acute infection model, has recently
been proposed as a risk factor for AD (Burgos et al., 2006;
Harris and Harris, 2015). A similar relationship has been
suggested for fungal infection and AD or ALS (Alonso et al.,
2015a,b; Pisa et al., 2015a,b). The field of potential vectors,
if restricted to well-adapted human pathogens, remains yet
undefined but many are already sequenced.
Theory
Curli from some human-adapted pathogens correspond to
multiple potentially infective natural misfolded protein fibrils
resulting from horizontal gene transfer (HGT) from agents well
adapted to the human host, acting at young ages as pluripotential
agents facilitating invasion, particularly during inflammatory
conditions (infections). These mechanisms may be shared by
some angiopathies and T2DM exhibiting a similar driver, as
well as by multiple similar pathogenic processes among humans.
An essential condition for bacterial agents being candidates
for HGT is that they themselves or their close ancestors
must have been well adapted to human hosts by integrating
pathogenic DNA (deoxyribonucleic acid) from different niches
(gingival, nasal, respiratory mucosae or gut epithelium, and
other). In essence, infection by E. coli or coexistent with
E. coli as a part of the intestinal microbiome, and other
well adapted human hosts carrying pathogenic human genetic
material and natural protein fibrils might induce diverse
sCNDD, T2DM, and atherosclerosis, following an age-at-
infection pattern.
MAIN FEATURES OF A CAUSAL
HYPOTHESIS FOR sCNDD,
ATHEROSCLEROSIS, AND T2DM
We propose that sCNDD, T2DM, a relevant proportion of
atherosclerosis, as well as other late-life endocrine disorders
resulting in andropause and estrogen deficit, constitute organ-
limited amyloid disorders, where conformational mimicry
leads to misfolding of a limited number of proteins such
as PrP, Langerhans Islet peptide, amyloid beta (Aβ), tau, α-
synuclein, SOD1, FTP-43, medin, TTR, and wild-type EFMP1
(Marmorstein et al., 2002).
Initial biological mechanisms are rooted in human genomics.
Eukaryotic DNA fragments implicated in genetic forms of
late-life NDDs [mainly AP and PD] incorporated in the
genome of potential commensal, symbiotic, and pathogenic
microorganisms present in the human reservoir, i.e., E. coli
and BP, constitute sequences resulting in pluripotential protein
fibrils that are infective via the respiratory and gastrointestinal
tract or by B lymphocyte presentation. Some amyloid proteins
such as APrP may additionally act parenterally by contact
with human misfolded protein fibrils, generating rapid course
sCNDD, such as sCJD, ALS, and some sRPNDds. Disease
progression and spread through the central nervous system
would follow reported anatomic patterns. Early vascular-wall
lesions determine the first steps in atherosclerotic plaque
formation. Small-vessel and neuronal lesions frequently
coexist. The same pathogenic mechanisms may underlie some
endocrine disorders. Multiple degenerative disorders may
share conformational pathophysiologic mechanisms linked
to different, as yet unknown, UPR. Latency intervals might
frequently encompass decades.
sCNDD epidemiologic patterns point to a high susceptibility
in late-infancy and at juvenile ages. Risk and disease spread can
be determined by the same factors, which constitute risk factors
or biomarkers of disease progression, or both. ER stressors
and UPR-related pathology, particularly late in life, may display
complex relationships, i.e., as seen for VRF, late-life sCNDD,
atherosclerosis, and T2DM. Incorporation of drivers 5,6, and 7
in the model seen in Figure 3, would result in a comprehensive
etiologic model presented in Figure 4.
IMPLICATIONS FOR RESEARCH
Components of the model seen in Figure 4 would have
implications for cohort alignment and experimental animal
research, as well as a for specific research outline proposals aimed
to test fragments of the abovementioned hypothesis.
Cohort Alignment
The present view of sCNDD reinforces the notion of a set of
neurodegenerative processes in which continuity as a form of
overlap, and competition—earlier andmore lethal NDDs, T2DM
or vascular disease removing persons at high risk of other less
lethal NDDs—act on the age axis. Equivalent, observational,
FIGURE 4 | Outline of an expanded Public Health Prevention Model II
to Model III for various conformational neurodegenerative, vascular
degenerative disorders and metabolic disorders (type 2 diabetes
mellitus), assuming unfolded protein response acts as a consequence
of at least two environmental causal mechanisms/agents, namely,
infection/inflammation by human-adapted microbiome (examples for
Bordetella pertussis (BP) and Escherichia coli) and invasive medical
procedures.
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proof-of-principle studies would correspond to investigations
aimed at confirming that NDDs which are clinically and
epidemiologically close by median age at onset, disease duration,
age-specific normalized incidence profile and genetic type of
change, share environmental risk factors. The study of exposures
in the first two decades of life would require approaches
separated from that of the same exposures at later ages, with
latency analyses being needed in both instances. Simultaneous
approaches including two or more NDDs may be advantageous.
Identification of selected populations by criteria targeted at
optimizing ascertainment of both exposure and outcome, plus
identification of randomly selected population controls are
paramount.
Experimental Animal Research
Implications of the driver notion from sCNDD epidemiology
in experimental research appear to be less direct than in
cohort alignment, requiring translation to biological inference.
Different animal models have been developed to address
various sCNDD, cardiovascular disease complications, and
T2DM. Models in mice targeting AD, tauopathies, and
ALS are mainly based on transgenic methodologies, with
those for PD and synucleinopathies being both toxic and
transgenic. Animal models may exhibit a number of important
limitations, mimicking phenotypic variants of AD and other
sCNDD1. The validity of human drivers, i.e., age-at-exposure
related susceptibility, may be tested in toxic animal models
of NDD.
In general, little attention has been paid to disease-
non-specific animal models based on seeding of naturally
produced amyloid fibrils, such as those generated by Sup35
from Saccharomyces cerevisiae, and curli from E. coli which
exert amyloid-accelerating influences in experimental murine
amyloidosis (Lundmark et al., 2005). In contrast, the validity
of traditional approaches is extensively considered in disease-
oriented media. A human driver-1-related, ApoE -/- mouse
model, is that which best fits the study of arteriosclerosis
and diabetes-accelerated arteriosclerosis (Zaragoza et al.,
2011). A similar feature displays the male-mouse castration
model of PD (Khasnavis et al., 2013). It would appear that
the most valid NDD models are the genetically-modified,
cell and animal models of AD, PD, FTD, and ALS, all of
which are based on the mutations described in the familial
NDD forms2. A research goal in the experimental model
context might be the identification of key elements underlying
an environmentally modified, potential effect of human
genes, similar to that shown by laboratory experiments
on NDDs, T2DM and atherosclerosis with traditional
models.
Specific attempts to combine population and clinical
cohorts/registries able to trace human events determining
current disease might be a priority, particularly if: (a) such events
1http://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-
actions/animal-and-cell-models.
2http://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-
actions/animal-and-cell-models.
can be identified by drivers; and (b) agents, similar to natural
fibrils used in seeding models reproducing amyloid disease
including NDDs, can be identified from historical sources, banks
or libraries.
NOTIONS FOR RESEARCH FRAMEWORK
DEVELOPMENT
Epidemiology
Traditionally, neuroepidemiologists have been used to working
with surveys or cohorts geographically settled close to their
residence. As a novelty, assessment and alignment of cohorts
for specific research purposes might be done for the first time
with a high number of population or clinical cohorts gathered
and offered as a potentially shared research resource3. On
the basis of best clinical and epidemiologic practice, research
into this avenue mighty advantageously address the etiology
of and risk factors for sporadic forms of CJD, sRPNDd,
MND, MSA, LBD, FTD, PD, AD, and AMD. This would
require work on populations exposed to biological environments
in specific conditions and with exposures measured under
extremely favorable conditions for epidemiologic comparisons
pertaining to registration and the time lag after exposure. Only
a few populations in the world would allow for such field
studies. To avoid misclassification of outcomes (subclinically
affected controls), studies on the very old should be extremely
cautious.
Possible factors to be weighted when considering favorable
research environments are:
• Populations with registered data on both sRPNDd and sCJD
tend to be large countries where CJD surveillance has been
conducted for decades, and NDD- as well as CJD-free clinical
controls have been registered.
• Medical procedures can be advantageously studied in
countries with national health services that provide health care
for the majority of their citizens.
• Controls randomly selected from annual population registries
are paramount for studies on risk from medical procedures.
• Historically, populations exposed to agents producing
point-source epidemics which are considerably separated
in time and act on the young population, have been
those that are geographically isolated with ancient native
populations <200,000. A minimum size or pooled study
would be required for substantial incidence counts of late-life
NDDs. Study populations of this nature are to be found in
Iceland, New Caledonia, San Miguel in the Azores (Aleixo-
Dias et al., 1993), and a few other islands.
• In order to reveal the causal nature of specific associations,
it might be advantageous to study the synergistic
effects observed between environmental exposures and
selected recognized genetic risk factors for different
entities.
3http://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-
actions/longitudinal-cohorts/.
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Experimental Work
Research of this nature might encompass:
• Identification of potential agents (well adapted, small genome)
with biological samples in potential vector libraries worldwide,
in cases where such agents are implicated in NDD incident in
high-risk cohorts;
• In silico identification of human genome fragments in
vectors exhibiting curly or natural fibrils potentially involved
in NDD induction, as seen from analysis of specific
cohorts;
• Protein aggregate characterization in biological samples
(bacteria, etc.), work with biofilms; and,
• development of animal models of defined or undefined
amyloid disorders, based on the seeding of natural fibrils
potentially involved in NDD induction.
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